Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology.
Bernard J. Escudier
Consultant or Advisory Role - Astellas Pharma; AVEO; Bayer-Schering; Genentech; GlaxoSmithKline; Novartis; Pfizer
Honoraria - AVEO; Bayer-Schering; Genentech; GlaxoSmithKline; Novartis; Pfizer
Sergio Bracarda
Consultant or Advisory Role - AVEO-Astellas; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi
José Pablo Maroto Rey
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Cezary Szczylik
Consultant or Advisory Role - AVEO; Bayer; Pfizer
Honoraria - Bayer; Pfizer
Paul D. Nathan
Consultant or Advisory Role - Novartis
Other Remuneration - Novartis
Sylvie Negrier
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Roche
Agnese Cattaneo
Employment or Leadership Position - Novartis
Claudia Weiss
Employment or Leadership Position - Novartis
Camillo Porta
Consultant or Advisory Role - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; Novartis
Viktor Gruenwald
Consultant or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche